Psyence Biomedical Ltd.

11/19/2026 | Press release | Distributed by Public on 11/19/2026 07:01

Condensed Consolidated Interim Statements of Financial Position (Form 6-K)

Condensed Consolidated Interim Statements of Financial Position

As at September 30, 2026 and March 31, 2026

USD $ Note

As at
September 30,
2026

(Unaudited)

As at

March 31,

2026

(Audited)

ASSETS
Current assets
Cash and cash equivalents 5 21,068,527 7,444,763
Restricted cash 5 71,810 47,191
Other receivables 57,738 109,779
Loan receivable 10 - 252,985
Prepaids 358,106 1,255,857
Total current assets 21,556,181 9,110,575
Non-current assets
Digital assets 8 495,646 389,758
Equipment 6 5,838 6,059
Investment in Associate 13 10,740,433 8,060,928
TOTAL ASSETS 32,798,098 17,567,320
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities 7 469,862 407,714
Derivative warrant liabilities 9 248,640 215,476
TOTAL LIABILITIES 718,502 623,190
SHAREHOLDERS EQUITY
Share Capital 12 95,605,014 78,747,983
Accumulated Deficit (65,320,683 ) (63,383,625 )
Warrant Reserve 1,065,705 1,065,705
Options Reserve 12 329,043 117,890
Reserves 400,517 396,177
TOTAL SHAREHOLDERS EQUITY 32,079,596 16,944,130
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY 32,798,098 17,567,320

Approved on behalf of Board of Directors

"Jody Aufrichtig" "Warwick Corden-Lloyd"
Chief Executive Officer and Director Chief Financial Officer and Director

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

2

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss

For three and six months ended September 30, 2026 and 2025

USD $ Note Three months ending
September 30,
2026
Three months ending
September 30,
2025
Six months ending
September 30,
2026
Six months ending
September 30,
2025
Expenses
Sales and marketing 105,506 48,670 119,646 154,976
Research and development 527,967 357,444 890,254 672,364
General and administrative 16 173,282 217,225 320,000 367,070
Professional and consulting fees 16 782,312 881,638 1,151,393 1,223,637
Loss before other items (1,589,067 ) (1,504,977 ) (2,481,293 ) (2,418,047 )
Other items
Depreciation 6 (1,486 ) (1,330 ) (2,802 ) (2,634 )
Interest expense (2,482 ) (2,753 ) (5,075 ) (5,125 )
Interest income 224,287 72,815 362,187 103,341
Other income 18 424,695 - 424,695 2,533
Foreign exchange (loss)/gain (2,531 ) 257 (971 ) (1,528 )
Fair value gain/(loss) on warrant liability 9 39,072 (58,016 ) (33,164 ) (98,272 )
Fair value gain on investment in Psyence Labs Ltd 13 - 740,750 - 427,000
Fair value gain on digital assets 8 165,868 - 105,888 -
Share of losses from Associate 13 (171,261 ) - (306,523 ) -
NET LOSS (912,905 ) (753,254 ) (1,937,058 ) (1,992,732 )
Other comprehensive income/(loss)
Foreign exchange (loss)/gain on translation (8,471 ) 636 4,340 (3,945 )
TOTAL COMPREHENSIVE LOSS (921,376 ) (752,618 ) (1,932,718 ) (1,996,677 )
Profit/(Loss) per share - basic & diluted (0.24 ) (3.18 ) (0.53 ) (11.76 )
Weighted average number of outstanding shares - basic & diluted 3,814,673 237,044 3,668,962 169,506

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

3

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

Condensed Consolidated Interim Statements of Changes in Shareholder Equity

For the six months ended September 30, 2026 and 2025

USD $ Note Number of
shares
Share capital Warrant
reserve
Options
Reserve
Reserves Accumulated
Deficit
Total
shareholders'
equity
Opening balance as at April 1, 2025 90,883 61,752,305 1,065,705 - 351,198 (56,447,204 ) 6,722,004
Issuance of shares to third party advisors 12 2,439 60,000 - - - - 60,000
Issuance of shares for ELOC, net of issuance costs 11/12 205,432 7,055,421 - - - - 7,055,421
Share based compensation 16 - - - 26,329 - - 26,329
Exercise of RSU's 12 774 16,884 - (16,884 ) - - -
Net loss for the period - - - - - (1,992,732 ) (1,992,732 )
Other comprehensive loss - - - - (3,945 ) - (3,945 )
Balance, September 30, 2025 299,528 68,884,610 1,065,705 9,445 347,253 (58,439,936 ) 11,867,077
Opening balance as at April 1, 2026 2,293,277 78,747,983 1,065,705 117,890 396,177 (63,383,625 ) 16,944,130
Issuance of shares for ELOC, net of issuance costs 11/12 1,519,383 16,780,447 - - - - 16,780,447
Share based compensation 16 - - - 287,737 - - 287,737
Exercise of RSU's 12 3,888 76,584 - (76,584 ) - - -
Net loss for the period - - - - - (1,937,058 ) (1,937,058 )
Other comprehensive income - - - - 4,340 - 4,340
Balance, September 30, 2026 3,816,548 95,605,014 1,065,705 329,043 400,517 (65,320,683 ) 32,079,596

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

4

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

Condensed Consolidated Interim Statements of Cash Flows

For the six months ended September 30, 2026 and September 30, 2025

Note Six months ending
September 30,
2026
Six months ending
September 30,
2025
Net (loss)/ income (1,937,058 ) (1,992,732 )
Non-cash adjustment:
Fair value loss on derivative warrant 9 33,164 98,272
Fair value gain on investment in Psyence Labs Ltd 13 - (427,000 )
Fair value gain on digital assets 8 (105,888 ) -
Share of losses from Associate 13 306,523 -
Third party advisors share issuance 12 - 60,000
Share based compensation 16 287,737 26,329
Depreciation 6 2,802 2,634
Foreign exchange 4,340 (3,945 )
Changes in working capital:
Other receivables 52,041 (36,839 )
Loan receivable 10 1,875 -
Prepaids 897,751 (6,296 )
Accounts payable and accrued liabilities 7 62,148 250,430
Cash used in operating activities (394,565 ) (2,029,147 )
Additions to equipment 6 (2,581 ) (228 )
Investment in Psyence Labs 13 (2,986,028 ) (4,000,000 )
Increase in restricted cash 5 (24,619 ) (11,227 )
Repayment of loan receivable 10 251,110 -
Cash used for investing activities (2,762,118 ) (4,011,455 )
Net proceeds received from ELOC 11 16,780,447 7,055,421
Cash provided from financing activities 16,780,447 7,055,421
Change in cash and cash equivalents 13,623,764 1,014,819
Cash and cash equivalents, beginning of period 7,444,763 6,135,166
Cash and cash equivalents, end of period 21,068,527 7,149,985

The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

5

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

Notes to the Condensed Consolidated Interim Financial Statements

1. Nature of operations

Psyence Biomedical Ltd. (the "Company" or "PBM"), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin and ibogaine-based neuroplastogen medicines. The Company is working towards developing psychedelic therapeutics to treat mental health disorders. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative care context (the "Clinical Trials").

The Company's registered office is at 121 Richmond Street West, PH Suite 1300, Toronto, Ontario M5H 2K1.

On November 26, 2024, the Company consolidated its common shares and warrants on the basis of 75:1.

On May 5, 2025, the Company consolidated its common shares and warrants on the basis of 7.97:1.

On February 2, 2026, the Company consolidated its common shares and warrants on the basis of 6.25:1.

All prior share capital information, including comparative figures, has been presented based on these ratios.

2. Basis of presentation

Statement of compliance

These Condensed Consolidated Interim Financial Statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain disclosures included in annual consolidated financial statements prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standards Board ("IFRS") have been condensed or omitted and these Unaudited Condensed Consolidated Interim Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements for the year ended March 31, 2026 and March 31, 2025. These Unaudited Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent annual consolidated financial statements.

The Condensed Consolidated Interim Financial Statements were authorized for issue on November 19, 2026 by the directors of the Company.

Basis of consolidation

These Condensed Consolidated Interim Financial Statements incorporate the accounts of PBM and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.

Control exists when an investor is exposed, or has the rights, to variable returns from the involvement with the investee and has the ability to affect those returns through its power over the investee.

The subsidiaries of PBM as at September 30, 2026 for the purpose of these Condensed Consolidated Interim Financial Statements are as follows:

Name of entity Place of incorporation % ownership Accounting method
Psyence Australia Pty Ltd. Australia 100 % Consolidated
Psyence Biomed II Corp. Canada 100 % Consolidated
Newcourt Acquisition Corp. Cayman Islands 100 % Consolidated
Texas Ibogaine Research Corporation United States 100 % Consolidated

6

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

Inter-company balances and transactions are eliminated upon consolidation.

Texas Ibogaine Research Corporation ("TIRC") was incorporated in the State of Texas on September 8, 2026 as a wholly owned subsidiary of Psyence Biomed II Corp.

Functional and presentation currency

These Condensed Consolidated Interim Financial Statements are presented in United States Dollars ("USD $"), which is also PBM's functional currency. The USD $ represents the currency of the Company's funding and is the currency of the primary economic environment in which the Company operates in, except for the Company's Australian subsidiary which has an Australian Dollar functional currency.

3. Material accounting policies

These Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent Annual audited Consolidated Financial Statements.

Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7) became effective for annual reporting periods beginning on or after January 1, 2026 and were adopted by the Company on April 1, 2026. The adoption of these amendments did not have a material impact on these Condensed Consolidated Interim Financial Statements.

Accounting Standards Issued But Not Yet Effective

A number of new standards, and amendments to standards and interpretations, are not yet effective for the period ended September 30, 2026, and have not been early adopted in preparing these consolidated financial statements.

IFRS 18 Presentation and Disclosure in Financial Statements

In April 2024, the IASB issued IFRS 18 - Presentation and Disclosure in Financial Statements which will replace IAS 1, Presentation of Financial Statements. The key new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial statements for certain earnings or loss performance measures that are reported outside an entity's financial statements and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the process of assessing the impact of this standard on its consolidated financial statements.

Other accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are not expected to have a significant impact on the Company's consolidated financial statements.

4. Critical accounting estimates and judgements

These Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent Annual audited Consolidated Financial Statements .

7

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

5. Cash, restricted cash and cash equivalents

Cash and cash equivalents include the following amounts:

September 30,
2026
March 31,
2026
Unrestricted cash held with chartered banks 21,068,527 7,444,763
Restricted cash 71,810 47,191
Total 21,140,337 7,491,954
● unrestricted cash and cash equivalents are held with chartered banks and an investment dealer, and include guaranteed investment certificates and term deposits; and
● the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $100,000 (March 31, 2026 - Canadian Dollars $65,000) in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the statements of financial position.

6. Equipment

Computer
equipment
Cost
Opening balance, April 1, 2025 15,604
Additions 228
At September 30, 2025 15,832
At March 31, 2026 15,833
Additions 2,581
At September 30, 2026 18,414
Accumulated Depreciation
Opening balance, April 1, 2025 (4,508 )
Charge for the period (2,634 )
At September 30, 2025 (7,142 )
At March 31, 2026 (9,774 )
Charge for the period (2,802 )
At September 30, 2026 (12,576 )
Carrying Value
At March 31, 2026 6,059
At September 30, 2026 5,838

7. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities include the following amounts:

September 30,
2026
March 31,
2026
Trade payables 377,906 229,509
Accrued liabilities 26,958 84,684
Provisions 64,998 93,521
Total 469,862 407,714

8

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

8. Digital assets

During the year ended March 31, 2026, the Company deposited $500,000 onto a financially regulated digital asset custody platform and used these funds to acquire a portfolio of cryptocurrencies. The portfolio is held for investment purposes and is accounted for as an intangible asset using the revaluation model in IAS 38 - Intangible Assets.

The following table summarizes the Company's digital asset holdings as at September 30, 2026 and March 31, 2026:

Asset

Symbol Quantity Fair Value
per Unit at
September 30,
2026
Fair value
September 30,
2026
Fair value
March 31,
2026
Revaluation
Increase
Bitcoin BTC 3.25 $ 83,552 $ 271,545 $ 221,762 $ 49,783
Ethereum ETH 35 $ 2,684 $ 93,950 $ 73,634 $ 20,316
Solana SOL 1,024 $ 118 $ 120,853 $ 85,064 $ 35,789
Tether USDT 1,000 $ 1 $ 1,000 $ 1,000 -
USD Coin USDC 1,000 $ 1 $ 1,000 $ 1,000 -
Cash (USD) 7,298 $ 1 $ 7,298 $ 7,298 -
Total $ 495,646 $ 389,758 $ 105,888

During the six months ended September 30, 2026, a revaluation gain of $105,888 (September 30, 2025 - $nil) was recognized in the condensed consolidated interim statements of net loss and comprehensive loss, being a reversal of revaluation decreases previously recognized in profit or loss. Fair values are determined by reference to quoted prices on active cryptocurrency exchanges (Level 1).

9. Derivative warrant liabilities

The Company has two classes of warrant liabilities outstanding: Public Warrants and Private Warrants. As of September 30, 2026 and March 31, 2026, there were 3,322 warrants issued and outstanding, consisting of 3,169 Public Warrants and 153 Private Warrants. Each warrant is exercisable to purchase one common share at a price of $42,963.28 per share.

Public Warrants: The fair value of the Public Warrants is determined based on the observable market price, as they continue to be traded on the Nasdaq under the symbol "PBMWW." Changes in fair value during the periods ended September 30, 2026 and September 30, 2025, have been recognized in the condensed consolidated interim statements of net loss and comprehensive loss.

Private Warrants: The Company utilizes a Black-Scholes options valuation model to value the private warrants at each reporting period, using the following main assumptions:

Warrant Inputs at

September 30, 2026

Warrant Inputs at

March 31,
2026

Share price $ 5.46 $ 2.46
Expected dividend yield Nil Nil
Exercise price $ 42,963.28 $ 42,963.28
Risk-free interest rate 4.21 % 4.21 %
Expected life 2.32 3.00
Expected volatility 59.98 % 59.98 %
Expiry date January 25, 2029 January 25, 2029

At September 30, 2026 the fair value of the Public and Private Warrants was $248,640 (March 31, 2026 - $215,476) and $nil (March 31, 2026 - $nil), respectively. A fair value loss of $33,164 (September 30, 2025 - $98,272 loss) was recognized on the condensed consolidated interim statements of loss and comprehensive loss.

9

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

The expected volatility was based on implied volatility of the Public Warrants.

As at September 30, 2026, the derivative warrant liability was reconciled as follows:

Derivative warrant liability - Public and Private Warrants

Number Amount ($)
Opening balance April 1, 2025 3,322 200,096
Fair value loss - 98,272
Balance as at September 30, 2025 3,322 298,368
Opening balance April 1, 2026 3,322 215,476
Fair value loss - 33,164
Balance as at September 30, 2026 3,322 248,640

Warrant transactions and the number of warrants outstanding are summarized as follows:

Public Warrants Private Warrants
Number of
Warrants
Weighted
Average
Exercise
Price
Number of
Warrants
Weighted
Average
Exercise
Price
Balance, April 1, 2025 3,169 $ 42,963.28 153 $ 42,963.28
Balance, September 30, 2025 and March 31, 2026 3,169 $ 42,963.28 153 $ 42,963.28
Balance, September 30, 2026 3,169 $ 42,963.28 153 $ 42,963.28

The following warrants were outstanding and exercisable at September 30, 2026:

Issue Date Expiry Date Exercise Price Number of Warrants
Outstanding
Number of Warrants
Exercisable
January 25, 2024 January 25, 2029 $ 42,963.28 3,322 3,322

10. Loan receivable

On February 9, 2026, the Company advanced a loan of $251,110 to Curiosum Ltd. (the "Loan") in connection with the settlement agreement with KAOS Capital Ltd. The Loan bore interest at RBC Prime Rate + 1% per annum and had a three-month term. As at March 31, 2026, the carrying amount of the Loan, including accrued interest of $1,875, was $252,985.

On May 19, 2026, the Loan was repaid in full together with accrued interest of $3,337. Interest income of $1,462 was recognized on the Loan during the six months ended September 30, 2026. As at September 30, 2026 the balance of the loan receivable was $nil.

10

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

11. ELOC

On August 28, 2024, the Company entered into a $25 million equity line of credit (ELOC) agreement with White Lion Capital, LLC, subsequently amended to $100 million, which was declared effective by the U.S. Securities and Exchange Commission (SEC). This agreement allows the Company to sell up to $100 million in shares up until December 31, 2027, subject to specific conditions outlined in the Purchase Agreement.

During the six months ended September 30, 2026 the Company issued 1,519,383 (September 30, 2025 - 205,432) common shares under the ELOC for total consideration of $16,931,511 (September 30, 2025 - $7,349,396). Share issuance costs of $151,064 (September 30, 2025 - $293,975) consisted entirely of cash settled share issuance costs.

12. Share capital

a) Authorized

The Company is authorized to issue an unlimited number of Common Shares, each without par value.

b) Issued and outstanding

On November 26, 2024, the Company consolidated its common shares on the basis of 75:1.

On May 5, 2025, the Company consolidated its common shares and warrants on the basis of 7.97:1.

On February 2, 2026, the Company consolidated its common shares and warrants on the basis of 6.25:1.

All common shares, warrants and value per share amounts have been updated to reflect the share consolidations.

As at September 30, 2026, there were 3,816,548 (September 30, 2025 - 299,528) issued and outstanding Common Shares.

Common shares Note 2026 2025
Number Amount ($) Number Amount ($)
Opening balance April 1 2,293,277 78,747,983 90,883 61,752,305
Shares issued for ELOC 11 1,519,383 16,931,511 205,432 7,349,396
Shares issued to third party advisors - - 2,439 60,000
Shares issued on RSU exercise 3,888 76,584 774 16,884
Share issuance costs 11 - (151,064 ) - (293,975 )
Balance as at September 30 3,816,548 95,605,014 299,528 68,884,610

Common shares

Issuance of shares to third party advisors

No common shares were issued to third party advisors during the six months ended September 30, 2026. In May 2025, the Company issued 2,439 common shares to various third party advisors in exchange for professional services.

11

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

c) Warrant Reserve

As at September 30, 2026, there were 41,656 (March 31, 2026 - 41,790) issued and outstanding Warrants. On August 20, 2026, 134 warrants exercisable at $1,867.97 per share expired unexercised.

The following warrants were outstanding and exercisable at September 30, 2026:

Issue Date Expiry Date Exercise
Price
Number of
Warrants
Outstanding
Number of
Warrants
Exercisable
December 24, 2024 December 24, 2029 $ 99.63 20,075 20,075
December 24, 2024 December 24, 2026 $ 99.63 20,075 20,075
December 24, 2024 December 24, 2029 $ 124.53 1,506 1,506

d) Restricted Stock Units (RSUs)

RSUs 2026 2025
Number
Opening balance April 1 9,636 -
RSU's granted 141,552 2,033
Exercised (3,888 ) (774 )
Cancelled (1,482 ) -
Balance as at September 30, 145,818 1,259

On June 1, 2026, the Company issued 141,552 RSUs to directors, consultants and employees which are exercisable into common shares of the Company at no additional cost and are to vest as follows:

● 47,184 exercisable on December 1, 2026
● 47,184 exercisable on June 1, 2027
● 47,184 exercisable on December 1, 2027

The fair value of the RSUs was determined to be $593,103 based on the fair value of the Company's common shares of $4.19 on the date of the grant. Upon exercise, the Company shall settle RSUs by way of common shares, with one (1) common share issued for every one (1) RSU exercised.

During the six months ended September 30, 2026, 3,888 RSUs were exercised into common shares and 1,482 RSUs were cancelled following the resignation of a consultant. Details of the RSUs granted on April 17, 2025 and October 1, 2025 are disclosed in the Company's audited consolidated financial statements for the year ended March 31, 2026.

13. Investment in Associate - Psyence Labs Ltd.

Psyence Labs Ltd. ("PsyLabs") is a private company headquartered in the British Virgin Islands focused on the production of psychedelic active pharmaceutical ingredients and extracts. On February 25, 2026, the Company's ownership interest in PsyLabs increased from 16.46% to 27.93% and the Company obtained significant influence over PsyLabs. From that date the investment has been accounted for as an investment in associate using the equity method in accordance with IAS 28 - Investments in Associates and Joint Ventures. Prior to that date the investment was classified as a financial asset at FVTPL, and an unrealized fair value gain of $427,000 was recognized on the investment during the six months ended September 30, 2025.

During August 2026, the Company acquired 242 PsyLabs shares from existing PsyLabs shareholders at $2,422 per share for total cash consideration of $586,124.

12

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

On September 9, 2026, PsyLabs issued a pre-emption notice and backstop subscription commitment to the Company in respect of a new issue of up to 2,138 PsyLabs shares at $2,564 per share, based on an equity valuation of $54,000,000. On September 16, 2026, the Company subscribed for 936 new PsyLabs shares for total consideration of $2,399,904. Under the backstop commitment, the Company agreed to subscribe for any shares not taken up by other PsyLabs shareholders, up to a maximum aggregate subscription amount of $2,600,000, in two milestone-based tranches. The remaining backstop commitment was taken up in full on October 16, 2026 (Note 19).

As at September 30, 2026, the Company held 7,078 PsyLabs shares, representing approximately 31.91% of PsyLabs' issued and outstanding shares.

The carrying amount of the investment in associate is reconciled as follows:

Investment in Associate
Carrying amount at March 31, 2026 8,060,928
Shares acquired from existing shareholders 586,124
Subscription for new shares 2,399,904
Share of associate net loss (306,523 )
Carrying amount at September 30, 2026 10,740,433

During the three and six months ended September 30, 2026, the Company recognized its share of PsyLabs' net loss of $171,261 and $306,523, respectively, which reduced the carrying amount of the investment.

14. Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.

The Company manages its capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents on hand.

To facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company's approach to capital management during the period.

13

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

15. Transactions with related parties

All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the periods ended September 30, 2026 and September 30, 2025:

Compensation to key management personnel

Key management personnel are those people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Directors.

Key Management Personnel September 30,
2026
September 30,
2025
Short term benefits 459,502 469,346
Share based compensation 202,683 22,996
Total 662,185 492,342

Short term benefits consist of consulting fees, director's fees, payroll and other benefits paid to key management personnel. This is included in the professional and consulting fees and general and administrative line items in the condensed consolidated interim statements of net loss and comprehensive loss.

Share-based compensation relates to RSUs granted to key management personnel.

During the six months ended September 30, 2026, the Company acquired 130 PsyLabs shares from certain existing PsyLabs shareholders that are related parties of the Company, at $2,422 per share (Note 13).

On September 25, 2026, TIRC and Psyence Labs Ltd. entered into a binding term sheet under which PsyLabs will grant TIRC an exclusive licence in the United States to PsyLabs' know-how and related intellectual property for its cGMP ibogaine HCl, appoint TIRC as its exclusive supplier and wholesale distributor of the product in the United States, and receive development milestone payments totaling up to approximately US$1.3 million for the first drug candidate, an annual exclusivity fee commencing on the first anniversary of the first FDA approval and creditable against royalties, and a low single-digit percentage royalty on net sales of each drug candidate, together with a margin-sharing arrangement on any resale of product by TIRC. As of the date of these financial statements, the Company has not met any of the milestones noted above.

16. Share based compensation

During the period ended September 30, 2026, $287,737 (September 30, 2025 - $26,329) was recognised for options and restricted stock units ("RSU's") granted by the Company under professional and consulting fees expenses and general and administrative expenses on the condensed consolidated interim statements of net loss and comprehensive loss.

14

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

17. Financial instruments and financial risk management

a) Financial instrument classification and fair value measurement

Financial instruments that are recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.

The fair value of hierarchy has the following levels:

● Level 1 - quoted prices in active markets for identical financial instruments.
● Level 2 - quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
● Level 3 - valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The table below presents the carrying value of the Company's financial instruments:

Level 1 Level 2 Level 3 Total
Digital assets 495,646 - - 495,646
Derivative warrant liabilities - public warrants 248,640 - - 248,640
Balance, September 30, 2026 744,286 - - 744,286
Digital assets 389,758 - - 389,758
Derivative warrant liabilities - public warrants 215,476 - - 215,476
Balance, March 31, 2026 605,234 - - 605,234

There were no transfers in and out of level 3 during the period.

b) Risk management

In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

Credit risk

Credit risk arises from cash, restricted cash and cash equivalents held with banks and investment dealers. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions.

15

PSYENCE BIOMEDICAL LTD.

Condensed Consolidated Interim Financial Statements (unaudited)

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company's main source of funding has been through equity investments and from government rebates in respect of research and development expenditure. The Company's access to financing is uncertain. There can be no assurance of continued access to significant equity or debt funding.

The following table set forth the maturity of the contractual obligations as at September 30, 2026 and after

Carrying
Amount
Contractual
Cash Flows
Less than 1
year
Between 1
and 3 years
Accounts payable & accrued liabilities 469,862 469,862 469,862 -
Total contractual obligations 469,862 469,862 469,862 -

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's cash equivalents include fixed-rate guaranteed investment certificates and term deposits, and variable-rate deposit accounts. Assuming balances at September 30, 2026 are maintained and fixed-rate deposits are reinvested on maturity, a 1% change in interest rates would change interest income over the following twelve months by $99,522. The Company has no interest-bearing liabilities.

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

As at September 30, 2026, a 10% fluctuation in foreign exchange rates would result in a $70,088 impact to net loss and comprehensive loss.

18. Other income

Other income for the six months ended September 30, 2026 of $424,695 (September 30, 2025 - $2,533) comprises insurance recoveries received from the Company's insurer in respect of legal fees incurred in connection with the shareholder dispute with KAOS Capital Ltd., which was settled in February 2026.

19. Subsequent Events

Subsequent to period end, the Company received gross proceeds of $8,374 for the issuance of 1,580 common shares in relation to the ELOC.

On October 12, 2026, directors, consultants and employees of the Company exercised 2,590 RSUs into common shares of the Company.

On October 1, 2026, the Company completed a share-for-share swap with PsyLabs pursuant to the Share-for-Share Swap and Nomination Agreement dated September 21, 2026. The Company issued 1,497,500 common shares to PsyLabs, at a deemed issue price of $6.00 per share (aggregate agreed value of $8,985,000), and in exchange PsyLabs issued 3,473 new PsyLabs ordinary shares to Psyence Biomed II Corp., as the Company's nominee, based on an agreed PsyLabs equity valuation of $60,000,000.

On October 16, 2026, the Company completed the second part of the PsyLabs equity raise, subscribing for a further 1,014 PsyLabs shares at $2,564 per share for total cash consideration of $2,599,896 under its backstop subscription commitment. Together with the 936 PsyLabs shares subscribed for in September 2026, the Company subscribed for 1,950 PsyLabs shares for total cash consideration of $4,999,800, representing approximately $5.0 million of the $5.5 million PsyLabs equity raise. Following this subscription and share-for-share swap, the Company holds 11,565 PsyLabs shares, representing approximately 43.37% of PsyLabs' issued and outstanding shares.

On November 10, 2026, Psyence Australia Pty Ltd received a research and development tax incentive rebate of AUD $1,034,681 ($710,363) from the Australian Taxation Office under the Australian Federal Government's Research and Development Tax Incentive Program, in respect of eligible research and development expenditure incurred in Australia. In accordance with the Company's accounting policy for government grants, the rebate will be recognized as other income in the period in which it was received.

16

Psyence Biomedical Ltd. published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 19, 2026 at 13:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]